Jazz Pharmaceuticals Plc · NASDAQ:JAZZ
Jazz Pharmaceuticals — Shareholder Meeting (July 2021)
25 slides from Jazz Pharmaceuticals's shareholder meeting presentation, Jul 14, 2021
Slide 1: 2021 Annual General Meeting
July 14, 2021 2021 Annual General Meeting
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements related to our strategy to create sustainable shareholder value, including statements related to the way we intend to advance our business, grow and diversify our revenues, and
Slide 3: Agenda and Overview of Share Issuance Proposals 4 and 5
2021 Annual General Meeting Agenda and Overview of Share Issuance Proposals 4 and 5 Our focus today is on Proposal 4 and Proposal 5 Under Irish law, our directors must have specific authorities from shareholders to allot and issue shares (PROPOSAL 4: share allotment and issuance authority) and to al
Slide 4: Enable efficient, attractive debt offerings; maintain strategic competitiveness
Enable efficient, attractive debt offerings Three exchangeable debt offerings, issued between 2014 and 2020, raised approximately $2B in capital at interest rates between 1.5% and 2.0% Authorities are generally required to issue new convertible or exchangeable notes for Jazz ordinary shares, and the
Slide 5: About Jazz Pharmaceuticals
About Jazz Pharmaceuticals 2021 Annual Meeting
Slide 6: Fully integrated, growing biopharmaceutical company in neuroscience and oncology
We are a fully integrated, growing biopharmaceutical company with a diverse portfolio of marketed medicines and novel product candidates in two key therapeutic areas: neuroscience and oncology. We are focused on developing life-changing medicines for people with serious diseases—often with limited o
Slide 7: Our Strategy to Create Sustainable Shareholder Value
Our Strategy to Create Sustainable Shareholder Value Strong commercial execution to drive revenue growth and diversification, and address unmet medical needs of our patients across our product portfolio Expanding and advancing our pipeline through internal and external patient-centric innovation to
Slide 8: Select Strategic Acquisitions and Transactions Since 2014
Select Strategic Acquisitions and Transactions Since 20141 2021 Annual Meeting 2014 2016 2020 Acquired US rights to lurbinectedin from Pharma Mar Acquired worldwide rights to JZP-150 from SpringWorks Therapeutics 2021 Acquired Gentium and rights to defibrotide in the Americas Acquired Sunosi rights
Slide 9: Strong Performance with Increasingly Diversified Revenues
Strong Performance with Increasingly Diversified Revenues Allocating Capital to Enhance Shareholder Returns 1 2017 to 2020 audited. 2 G=Guidance. 2021 Guidance provided by Jazz Pharmaceuticals plc on and as of June 17, 2021. The prior guidance is not being updated or confirmed, and actual results ma
Slide 10: We Are Listed in the U.S. and Incorporated in Ireland
We Are Listed in the U.S. and Incorporated in Ireland We are incorporated in Ireland Our ordinary shares are listed exclusively on the Nasdaq Global Select Market We are required to follow the corporate legal requirements of Ireland We are a U.S. domestic reporting company under SEC rules; we are no
Slide 11: Share Issuance Proposals
Share Issuance Proposals PROPOSALS 4 AND 5 2021 Annual Meeting
Slide 12: What are the Share Issuance Proposals?
What are the Share Issuance Proposals? Share allotment and issuance authority Proposal to renew, for a new 5-year term, our directors’ authority to allot and issue ordinary shares up to our authorized but unissued share capital The board of directors recommends a vote FOR Proposal 4 The board of dir
Slide 13: Renewal of Share Issuance Authorities is Fundamental to Our Strategy
The Renewal of Our Share Issuance Authorities is Fundamental to Our Strategy The renewal of our share issuance authorities is fundamental to the way we intend to advance our business, grow and diversify our revenues and increase shareholder value Our growth strategy depends in part on our ability to
Slide 14: Nearly Ten Years of Disciplined Use of Equity
For Nearly Ten Years, We Have Demonstrated Disciplined Use of Equity During our nearly ten years as an Irish-incorporated company, our shareholders have entrusted us to be disciplined stewards of our current share issuance authorities—our actions during that time demonstrate our deliberately discipl
Slide 15: Our Share Issuance Proposals are Critical
Our Share Issuance Proposals are Critical Why Should You Support Our Share Issuance Proposals? If the share issuance proposals are not approved, our current share issuance authorities will expire on August 4, 2021 and without further shareholder approval: we will generally not be able to issue share
Slide 16: Adjournment Proposal
Adjournment Proposal PROPOSAL 6 2021 Annual Meeting
Slide 17: What is the Adjournment Proposal?
What is the Adjournment Proposal? Proposal 5 (Renewal of existing pre-emption opt-out authority) requires that at least 75% of the votes cast (in person or by proxy) be voted “FOR” the proposal in order to be passed If you support Proposal 5, we believe that a vote for Proposal 6, the adjournment pr
Slide 18: Shareholder Engagement, ESG and Executive Compensation
2021 Annual Meeting Shareholder Engagement, ESG and Executive Compensation
Slide 19: We Regularly Solicit and Act On Shareholder Input
We Regularly Solicit and Act On Shareholder Input Our directors and management team engage as appropriate with shareholders on a variety of topics including governance, executive compensation, and a variety of environmental & social issues With respect to our compensation program: The compensation c
Slide 20: ESG Highlights
ESG Highlights Our Nominating & Corporate Governance Committee has oversight responsibilities for ESG strategy and practices While we have a broad suite of ESG initiatives that cross the environmental, social, and governance terrains that includes our patients and our communities, our internal prior
Slide 21: Post-Meeting Board: Director Independence, Tenure and Diversity
Post-Meeting Board: Director Independence, Tenure and Diversity Our board is substantially independent and has a mix of relatively newer and longer-tenured directors. The board includes one racially/ethnically diverse director, and one director who identifies as LGBTQ+. 2021 Annual Meeting Director
Slide 22: Compensation Philosophy and Objectives
Compensation Philosophy and Objectives Our executive compensation program is designed with the following objectives and philosophy: Attract, incentivize, reward and retain diverse, talented individuals with relevant experience in the life sciences industry through a competitive pay structure Deliver
Slide 23: Logistics
2021 Annual Meeting Logistics 2021 Annual Meeting
Slide 24: We Value Your Support at the 2021 Annual General Meeting
We Value Your Support at the 2021 Annual General Meeting By phone by calling 1-800-690-6903 (your vote must be received by 11:59 p.m. U.S. Eastern Time on July 28, 2021 for your vote to be counted) Online at www.proxyvote.com (your vote must be received by 11:59 p.m. U.S. Eastern Time on July 28, 20
Slide 25: 2021 Annual General Meeting
July 14, 2021 2021 Annual General Meeting
Jazz Pharmaceuticals — Shareholder Meeting (July 2021) on 6ix